Cardiac amyloidosis pathophysiology

Jump to navigation Jump to search

Cardiac amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiac Amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cardiac amyloidosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac amyloidosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac amyloidosis pathophysiology

CDC onCardiac amyloidosis pathophysiology

Cardiac amyloidosis pathophysiology in the news

Blogs on Cardiac amyloidosis pathophysiology

Directions to Hospitals Treating Cardiac amyloidosis

Risk calculators and risk factors for Cardiac amyloidosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]Sabawoon Mirwais, M.B.B.S, M.D.[4]

Overview

The characteristic feature of cardiac amyloidosis is abnormal deposition of abnormally folded light chains of several serum proteins, making them insoluble and leading to their accumulation in various organs. This abnormal folding of proteins is most commonly a result of genetic mutations or excessive formation. Involvement of cardiac muscle can lead to heart failure, arrhythmias, and advanced cardiac conduction disorders.

Pathophysiology

Pathogenesis

Acquired Monoclonal Immunoglobulin Light-chain Amyloidosis (AL)

Hereditary Transthyretin (TTR)-Related Form (ATTR)

  • The hereditary or familial form of cardiac amyloidosis is inherited in an autosomal dominant pattern. Mutations leading to substitution of a single amino acid on the protein chain can cause abnormal spacial configuration of the protein, leading to its abnormal deposition in the inter-cellular space.
  • The mutations in the genes producing various proteins like transthyretin, fibrinogen, apolipoprotein A1 and A2 are responsible. However, the transthyretin mutation is by far the most common cause of hereditary cardiac amyloidosis.
  • Transthyretin, a protein tetramer synthesized in the liver, is responsible for transport of the thyroid hormone and vitamin A in the body. The extent of myocardial involvement varies with the gene sequence mutated in the transthyretin gene.
  • About 90 to 100% of patients with "Thr60Ala" mutation, where alanine is substituted for threonine at the 60th position on the transthyretin protein and the "Val122Ile", in which isoleucine is substituted for valine at the 122nd amino acid position, have severe restrictive cardiomyopathy at presentation.
  • The "Val30Met" mutation of transthyretin has cardiac involvement only in the elderly patients, with peripheral and autonomic nervous system being the primary target. The Val30Met mutation is normally present in 3.9% of all African Americans and in about 23% of African Americans with cardiac amyloidosis.[9]
  • Cardiac involvement is rare in other variant ATTR like mutations in apolipoprotein A1 and secondary amyloidosis. These more often involve the liver and kidneys.

Senile Systemic Amyloidosis (Non-mutant TTR-related amyloidosis, Wild Type ATTR)

  • Amyloid deposits are found in the hearts of approximately 25% of elderly patients at autopsy.[9] The clinical significance of these amyloid deposits has not been elucidated, although excess deposition leading to symptoms has been shown to be associated with increased mortality, with a median survival of 7 years following the onset of symptoms.[10][11][12]
  • This type of amyloidosis predominantly involves the heart, with the exception of Carpal tunnel syndrome , which presents about 3 to 4 years before cardiac failure.
  • This disorder shows male preponderance and commonly presents after 60 years of age. This condition is often misdiagnosed as chronic hypertension, but recent diagnostic techniques like cardiac MRI have made possible the diagnosis of this condition. It is probably the most common form of amyloidosis in the United States.
  • Senile systemic amyloidosis has been associated with increased incidence of myocardial infarctions[13] and atrial fibrillation[14] in various studies. The association of tau protein with occurrence of this condition has raised the question of correlation of senile systemic amyloidosis with Alzheimer's disease.

Isolated Atrial Amyloidosis (IAA)

  • In isolated atrial amyloid deposition the deposition is limited solely to the atria.
  • This condition most commonly results from excess production of abnormally folded atrial natriuretic peptide, like in congestive cardiac failure and valvular heart disease. The amount of amyloid deposited in the atrium correlates with patient's age and P wave duration, which is associated with the magnitude of delay in atrial conduction.[15][16]
  • The incidence of this condition increases with age with a female preponderance.[17] IAA first presents in the fourth decade of life, and there is an increased incidence of 15 to 20% per decade of life. More than 90% of the patients with isolated atrial amyloidosis are in their ninth decade of life.[15]
  • Increased incidence of atrial fibrillation[18] and other tachyarrhythmias has been noted in patients with isolated atrial amyloidosis.[19]

Other Types of Amyloidosis

  • Chronic inflammation causing systemic AA amyloidosis involves the heart tissue in only 2% of the patients, causing heart failure and arrhythmias.
  • The incidence of this type of cardiac amyloidosis is progressively decreasing signifying better treatment of rheumatological disorders and chronic infections.

Atrial Fibrillation in Cardiac Amyloidosis

  • Autonomic imbalance, degenerative tissue changes, alterations in intercellular matrix and fibrosis increase the likelihood of developing atrial fibrillation in patients with cardiac amyloidosis. Increased amounts of fibrous tissue in the extracellular space disturbs the cell-to-cell coupling, thereby directly affecting conduction.
  • In a study done by Leone et al.[20] in patients with chronic persistent AF, amyloid deposits were found mainly in the left atrial appendages. On microscopic analysis, the deposition was predominantly along the sarcolemma of myocytes with minimal involvement of the endocardium.

Genetics

  • Cardiac amyloidosis, in the setting of familial or hereditary amyloidosis, can involve mutations in the following genes:[21]
    • LYZ gene
    • Fibrinogen A alpha polypeptide gene
    • FGA gene
    • APOA1 gene
    • Lysozyme gene
    • B2M gene

Associated Conditions

Gross Pathology

Cardiac amyloid deposits are most commonly seen in the myocardium, but can also be seen in the atria, pericardium, endocardium and microvasculature.

  • On gross examination, the myocardium is thicker, firm and rubbery in consistency. More than half of myocardium involvement is common in the AL type of cardiac amyloidosis.
  • The size of the ventricular cavity remains unchanged, however filling of the ventricles is restricted (causing restrictive cardiomyopathy) because of stiffening of the ventricular wall as a result of deposition of amyloid material.
  • Pericardial effusion and valvular dysfunction is common from pericardial and endocardial involvement. Intracardiac thrombus formation is frequently seen and may result in fatal thromboembolism.[22][23][24]

Images shown below are courtesy of Professor Peter Anderson and published with permission. © PEIR, University of Alabama at Birmingham, Department of Pathology

Amyloidosis Lesion In Left Atrium: Gross natural color view of a diagnostic lesion
Amyloidosis Lesion In Left Atrium: Gross natural color close-up
Amyloidosis, left atrium, endocardial nodules
Amyloidosis, left atrium, endocardial nodules
Amyloidosis and left ventricular hypertrophy


Microscopic Pathology

  • Under light microscope, extracellular deposits of hyaline like amyloid material are evident. Resultant myocardial fibrosis restricts the movement of the ventricle, compromising complete filling of the ventricle during diastole.
  • Amyloid deposits are also seen in the vasculature, particularly the microvasculature thereby sparing the large epicardial vessels. This leads to myocardial ischemia and tissue infarction.
Heart: Perivascular amyloid, amyloidosis, congo red showing birefringence
Heart: Perivascular amyloid, amyloidosis (Hematoxylin and eosin staining)
Heart: Amyloidosis, aldehyde fuchsin stain


References

  1. Merlini G, Bellotti V (2003). "Molecular mechanisms of amyloidosis". The New England Journal of Medicine. 349 (6): 583–96. doi:10.1056/NEJMra023144. PMID 12904524. Retrieved 2012-02-13. Unknown parameter |month= ignored (help)
  2. Martinez-Naharro A, Hawkins PN, Fontana M (April 2018). "Cardiac amyloidosis". Clin Med (Lond). 18 (Suppl 2): s30–s35. doi:10.7861/clinmedicine.18-2-s30. PMC 6334035. PMID 29700090.
  3. Martinez-Naharro A, Hawkins PN, Fontana M (April 2018). "Cardiac amyloidosis". Clin Med (Lond). 18 (Suppl 2): s30–s35. doi:10.7861/clinmedicine.18-2-s30. PMC 6334035. PMID 29700090.
  4. Dharmarajan K, Maurer MS (2012). "Transthyretin cardiac amyloidoses in older North Americans". Journal of the American Geriatrics Society. 60 (4): 765–74. doi:10.1111/j.1532-5415.2011.03868.x. PMC 3325376. PMID 22329529. Unknown parameter |month= ignored (help)
  5. Falk RH (September 2005). "Diagnosis and management of the cardiac amyloidoses". Circulation. 112 (13): 2047–60. doi:10.1161/CIRCULATIONAHA.104.489187. PMID 16186440.
  6. Falk RH, Comenzo RL, Skinner M (1997). "The systemic amyloidoses". The New England Journal of Medicine. 337 (13): 898–909. doi:10.1056/NEJM199709253371306. PMID 9302305. Retrieved 2012-02-13. Unknown parameter |month= ignored (help)
  7. Gertz MA, Lacy MQ, Dispenzieri A (1999). "Amyloidosis: recognition, confirmation, prognosis, and therapy". Mayo Clinic Proceedings. Mayo Clinic. 74 (5): 490–4. doi:10.4065/74.5.490. PMID 10319082. Retrieved 2012-02-13. Unknown parameter |month= ignored (help)
  8. Martinez-Naharro A, Hawkins PN, Fontana M (April 2018). "Cardiac amyloidosis". Clin Med (Lond). 18 (Suppl 2): s30–s35. doi:10.7861/clinmedicine.18-2-s30. PMC 6334035. PMID 29700090.
  9. 9.0 9.1 Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD (2012). "Updates in cardiac amyloidosis: a review". Journal of the American Heart Association. 1 (2): e000364. doi:10.1161/JAHA.111.000364. PMC 3487372. PMID 23130126. Unknown parameter |month= ignored (help)
  10. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH (2005). "Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis". Archives of Internal Medicine. 165 (12): 1425–9. doi:10.1001/archinte.165.12.1425. PMID 15983293. Unknown parameter |month= ignored (help)
  11. Hodkinson HM, Pomerance A (1977). "The clinical significance of senile cardiac amyloidosis: a prospective clinico-pathological study". The Quarterly Journal of Medicine. 46 (183): 381–7. PMID 918253. Retrieved 2012-02-13. Unknown parameter |month= ignored (help)
  12. Lie JT, Hammond PI (1988). "Pathology of the senescent heart: anatomic observations on 237 autopsy studies of patients 90 to 105 years old". Mayo Clinic Proceedings. Mayo Clinic. 63 (6): 552–64. PMID 3374172. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  13. Tanskanen M, Peuralinna T, Polvikoski T; et al. (2008). "Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study". Annals of Medicine. 40 (3): 232–9. doi:10.1080/07853890701842988. PMID 18382889.
  14. Falk RH, Dubrey SW (2010). "Amyloid heart disease". Progress in Cardiovascular Diseases. 52 (4): 347–61. doi:10.1016/j.pcad.2009.11.007. PMID 20109604.
  15. 15.0 15.1 Goette A, Röcken C (2004). "Atrial amyloidosis and atrial fibrillation: a gender-dependent "arrhythmogenic substrate"?". European Heart Journal. 25 (14): 1185–6. doi:10.1016/j.ehj.2004.04.014. PMID 15246635. Unknown parameter |month= ignored (help)
  16. Millucci L, Ghezzi L, Bernardini G, Braconi D, Tanganelli P, Santucci A (2012). "Prevalence of isolated atrial amyloidosis in young patients affected by congestive heart failure". TheScientificWorldJournal. 2012: 293863. doi:10.1100/2012/293863. PMC 3317626. PMID 22536133.
  17. Steiner I (1987). "The prevalence of isolated atrial amyloid". The Journal of Pathology. 153 (4): 395–8. doi:10.1002/path.1711530413. PMID 3430237. Unknown parameter |month= ignored (help)
  18. Röcken C, Peters B, Juenemann G; et al. (2002). "Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation". Circulation. 106 (16): 2091–7. PMID 12379579. Unknown parameter |month= ignored (help)
  19. Ariyarajah V, Steiner I, Hájková P; et al. (2009). "The association of atrial tachyarrhythmias with isolated atrial amyloid disease: preliminary observations in autopsied heart specimens". Cardiology. 113 (2): 132–7. doi:10.1159/000177950. PMID 19039221.
  20. Leone O, Boriani G, Chiappini B; et al. (2004). "Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation". European Heart Journal. 25 (14): 1237–41. doi:10.1016/j.ehj.2004.04.007. PMID 15246642. Unknown parameter |month= ignored (help)
  21. Pepys MB, Hawkins PN, Booth DR, Vigushin DM, Tennent GA, Soutar AK, Totty N, Nguyen O, Blake CC, Terry CJ (April 1993). "Human lysozyme gene mutations cause hereditary systemic amyloidosis". Nature. 362 (6420): 553–7. doi:10.1038/362553a0. PMID 8464497.
  22. Nakagawa M, Tojo K, Sekijima Y, Yamazaki KH, Ikeda S (2012). "Arterial thromboembolism in senile systemic amyloidosis: report of two cases". Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis. 19 (2): 118–21. doi:10.3109/13506129.2012.685131. PMID 22583098. Unknown parameter |month= ignored (help)
  23. Van de Veire NR, Dierick J, De Sutter J (2012). "Intracardiac emboli as first presentation of cardiac AL amyloidosis". European Heart Journal. 33 (7): 818. doi:10.1093/eurheartj/ehr330. PMC 3345559. PMID 21893485. Unknown parameter |month= ignored (help)
  24. Feng D, Edwards WD, Oh JK; et al. (2007). "Intracardiac thrombosis and embolism in patients with cardiac amyloidosis". Circulation. 116 (21): 2420–6. doi:10.1161/CIRCULATIONAHA.107.697763. PMID 17984380. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources CME Category::Cardiology